-
Beijing Medical Insurance: 74 new reimbursable drugs will be added from next month, a drop of more than half
Time of Update: 2022-01-08
It is reported that after the implementation of the reimbursement policy for special diseases in outpatient clinics in Beijing, the average annual cost of using the drug for retired employees will be further reduced to about 18,000 yuan, and the price reduction will be greatly increased .
-
Gospel of dry eye!
Time of Update: 2022-01-08
Recently, Novaliq announced that the second pivotal phase 3 clinical trial of CyclASol, a topical anti-inflammatory eye drops under investigation, for the treatment of dry eye (DED) has achieved positive results .
Retrieved December 21, 2021, from https:// /21/novaliq-announces-positive-topline-results-for-second-phase-3-trial-essence-2-of-cyclasol-in-dry-eye-disease/[2] Sheppard, JD, et, al.
-
The Chinese medicine industry has ushered in a major reshuffle. How should relevant companies respond?
Time of Update: 2022-01-08
At present, in order to better promote the innovation and development of traditional Chinese medicine equipment, a large number of pharmaceutical equipment companies in China have begun to practice their internal skills one after another, striving to produce high-quality, sophisticated, and cutting-edge equipment, staying away from low-level competition, and further helping the Chinese medicine industry to achieve high-quality Direction development .
-
The Chinese patent medicine market is showing a trend of polarization!
Time of Update: 2022-01-08
From 2017 to 2019, the market size of traditional Chinese medicine formula granules has increased from 16.
Everbright Securities believes that the Chinese medicine sector has the logic of steady growth in domestic consumption, policies to encourage high-quality development, and continuous price increases.
-
Into the field of pharmaceutical separation and purification, explore the space worth exploring
Time of Update: 2022-01-08
After years of scientific and technological development, a large number of new technologies and methods have emerged in the separation and purification of pharmaceuticals in China, such as macroporous resin adsorption, high-speed countercurrent chromatography separation technology, ultrafiltration membrane technology, etc.
-
Encouraging policy intensive support, the Chinese medicine industry ushered in new opportunities for development
Time of Update: 2022-01-08
In the future, with the support of a series of favorable policies, the pace of development of Chinese medicine will continue to accelerate .
-
Innovation is not easy, a large number of pharmaceutical companies will terminate the research and development of innovative drugs in 2021
Time of Update: 2022-01-08
According to incomplete statistics, in 2021, domestic companies such as Biotech, Renfu Pharmaceutical, and Zejing Pharmaceutical have terminated the research and development of a batch of innovative drugs under its umbrella .
-
Zai Lab CLDN 18.2 monoclonal antibody applied for clinical application in China
Time of Update: 2022-01-08
Article source: Medical Rubik's Cube InfoAuthor: SunshineOn December 30, the official website of CDE showed that Zai Lab's CLDN18.
Claudin (CLDN) protein is one of the important components of the tight junctions of epithelial cells.
2 monoclonal antibody developed by Zai Lab .
-
Within a week, domestic pharmaceutical companies introduced 2 new drugs
Time of Update: 2022-01-08
On December 29, Shanghai AG Baifa announced that its subsidiary Ark Biopharmaceutical Limited and Commave Therapeutics, SA (Commave) under Gurnet Point Capital (GPC) have signed an exclusive license agreement to trade an innovative drug AZSTARYS® for the treatment of ADHD .
-
Reduce prices and control fees throughout the policy-oriented drive innovation and development of enterprises
Time of Update: 2022-01-08
By 2021, the first year of the Fourteenth Five-Year Plan, China's medical industry has undergone a series of policy adjustments, the framework has basically taken shape, and the overall policy for drug access, pricing, procurement, use, and payment has been determined .
-
Favorable policies were introduced intensively at the end of the year, and the innovative drug industry attracted the attention of the industry
Time of Update: 2022-01-08
" The notice shows that in order to improve the efficiency of the research and development of such drugs and standardize the design of clinical trials, the Center for Drug Evaluation has organized and written the "Technical Guidelines for Clinical Evaluation of Intravenous Anesthetics" and formed a draft for comments.
-
Remission rate reaches 62% Janssen submits bispecific antibody marketing application
Time of Update: 2022-01-08
Today, Johnson & Johnson's Janssen Company (Janssen) announced that it has submitted a biologics license application (BLA) for teclistamab to the US FDA for the treatment of relapsed or refractory (R/R) multiple myeloma (MM) Patient .
Retrieved December 29, 2021, from https:// submits-biologics-license-application-to-us-fda-seeking-approval-of-teclistamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301451472.
-
The results of the first collection of proprietary Chinese medicines were announced: the biggest drop was 82.63%!
Time of Update: 2022-01-08
This month, the results of the first centralized procurement of Chinese patent medicines (Hubei 19 Provincial Alliance) were released .
In addition to Hubei this year, the 6-province alliance of Guangdong has conducted centralized procurement of proprietary Chinese medicines, and it is now coming to an end .
-
Regulatory policies and favorable policies go hand in hand, and the Chinese medicine industry will usher in a major reshuffle!
Time of Update: 2022-01-08
The new version of the Pharmacopoeia implemented on December 30, 2020 has more stringent requirements for drug safety, and specifies strict management of planting, collection, processing and circulation in the traditional Chinese medicine decoction piece industry, so as to improve the quality of traditional Chinese medicine products and promote the high quality of the industry developing .
-
Three major national talks have been added to the Internet, involving pharmaceutical companies such as Hengrui and Buchang
Time of Update: 2022-01-08
On December 29, the Shanghai Sunshine Collection Network issued a "Notice on the Online Purchase of Newly-added Medical Insurance Negotiation Drugs in Some Countries (Second Batch)", which included three national pharmaceutical companies such as Hengrui Medicine and Shandong Buchang.
-
Review of Ten Maps of the Pharmaceutical Industry in 2021
Time of Update: 2022-01-08
The shadow of "auxiliary medication"In recent days, the share prices of some listed Chinese medicine companies have soared, either because of the increase in the price of medicinal materials, or because they have made up for the decline, or because they have become a safe haven for innovation and involution of funds.
-
In the past week, institutions have intensively investigated a number of listed pharmaceutical companies
Time of Update: 2022-01-08
According to data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical preparations .
In response to investors’ questions, Teyi Pharmaceutical said that Zhikebao Tablets are currently the company’s key product and also the company's core product.
-
Fosun Pharma terminates the development of the introduced SGLT-2 inhibitor
Time of Update: 2022-01-08
Up to now, the total R&D investment in this new drug project is approximately RMB 55.
In 2020, the sales of SGLT-2 inhibitors in China will be approximately RMB 966 million .
-
"Growth hormone" quickly "out of the circle", Anke Bio-Human Growth Hormone Injection was approved to increase 2 indications
Time of Update: 2022-01-08
. The author was informed that, in addition to the above-mentioned breakthroughs in the human growth hormone injection field by Anke Biotech, Jichuan Pharmaceuticals recently issued an announcement stating that the company is expected to spend more than 2 billion yuan to obtain Tianjing Biotech through the License-in (licensed introduction) model.
-
In 2022, multinational pharmaceutical companies will continue to accelerate their "weight reduction" in China
Time of Update: 2022-01-08
The industry believes that the layoffs of the above-mentioned multinational pharmaceutical companies in China are actually not Nothing new .
In addition to layoffs, in fact, many multinational pharmaceutical companies including Pfizer, Roche, Merck and other companies have adjusted their organizational structures in China since the beginning of this year.
